Full-Time

Scientist / Sr. Scientist

Posted on 10/31/2025

UntilLabs

UntilLabs

51-200 employees

Advances reversible organ cryopreservation technology

Compensation Overview

$120k - $180k/yr

California, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Biochemistry
Requirements
  • 4+ years of industry experience or PhD/Postdoc training in Bioengineering, Synthetic Biology, Chemical Engineering, Biochemistry, Neuroscience, Immunology, or a related field
  • track record of scientific excellence and autonomy, with the ability to independently develop and carry out complex experiments
  • collaborative mindset and ability to work with diverse perspectives
Responsibilities
  • Develop innovative approaches to characterize toxicity and permeability of new compounds and their interactions with cells and organs
  • Build clinically translatable healthy in vitro models using primary cells/tissues (Kidney, Liver, Heart, etc.)
  • Design and implement high-throughput screening (HTS) experiments at cellular, 3D in vitro model, and tissue levels
  • Analyze HTS data to identify promising materials and biological interactions that support project objectives
  • Apply genomics techniques such as GWAS, RNAseq, and FISH to inform and refine molecular discovery and in vitro models
  • Collaborate closely with cross-functional teams to translate experimental findings into new cryoprotectant solutions for human-sized organ preservation
Desired Qualifications
  • Experience with primary cell culture and tissues (Kidney, Liver, Heart, etc.) strongly preferred
  • Expertise in developing and maintaining advanced in vitro models to support discovery and translational research
  • Proficiency with genomics platforms and analytical methods (e.g., GWAS, RNA sequencing, FISH)
  • Programming and operating liquid handling robotics to enable high-throughput workflows
  • Instrumentation techniques for chemical characterization, including DSC, HPLC, GC/LCMS, and FPLC
  • Ability to evaluate drug pharmacokinetics and pharmacodynamics to inform preclinical development

UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

San Francisco, California

Founded

2024

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $58M Series A in September 2025 from Founders Fund, Lux Capital, Field Ventures.
  • Enables organ banking, better matching, reduces waitlist deaths from time constraints.
  • Foundational for whole-body preservation, backed by over $100M funding.

What critics are saying

  • FDA lacks approval framework, delaying commercialization 3-5 years.
  • Normothermic systems from OrganOx, Transmedics capture market pre-approval.
  • Cryoprotectant toxicity triggers rejection, forces redesign in 24-36 months.

What makes UntilLabs unique

  • Until Labs develops reversible cryopreservation for organs using vitrification without ice formation.
  • Engineers five dimensions: perfusion, cryoprotectants, cooling, rewarming, and post-thaw assays.
  • Progressed from neural slices to preclinical kidneys, hearts, lungs, livers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Flexible Work Hours

Paid Holidays

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Commuter Benefits

Professional Development Budget

Company News

Pioneer Publishers
Sep 22nd, 2025
Until Labs Secures $58M for Cryopreservation

Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.

Fenwick
Sep 22nd, 2025
Fenwick Represents Until Labs in $58M Series A Funding

Fenwick represents Until Labs in $58M Series A funding.

INACTIVE